نتائج البحث - Anitra Fielding

  • يعرض 1 - 20 نتائج من 20
تنقيح النتائج
  1. 1
    Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir

    Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir حسب Gary J. Muirhead, Maria Wulff, Anitra Fielding, Diane Kleinermans, Neil Buss

    منشور في 2000
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration

    Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration حسب Lynn Purkins, Nolan Wood, Parviz Ghahramani, Edward R. Love, Malcolm D. Eve, Anitra Fielding

    منشور في 2003
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer

    Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic can... حسب J.C. Bendell, Eileen M. O’Reilly, Mark R. Middleton, Ian Chau, Howard S. Höchster, Anitra Fielding, Wendy Burke, Howard A. Burris

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Olaparib efficacy in patients with germline <scp>BRCA</scp>‐mutated, <scp>HER2</scp>‐negative metastatic breast cancer: Subgroup analyses from the phase <scp>III OlympiAD</scp> trial

    Olaparib efficacy in patients with germline <scp>BRCA</scp>‐mutated, <scp>HER2</scp>‐negative metastatic breast cancer: Subgroup analyses from the phase <scp>III OlympiAD</scp> tri... حسب Elżbieta Senkus, Suzette Delaloge, Susan M. Domchek, Pierfranco Conté, Seock‐Ah Im, Binghe Xu, Anne Armstrong, Norikazu Masuda, Anitra Fielding, Mark E. Robson, Nadine Tung

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

    Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the main... حسب Brian Dougherty, Zhongwu Lai, Darren Hodgson, Maria Orr, Matthew Hawryluk, James Sun, Roman Yelensky, Stuart Spencer, Jane Robertson, Tony W. Ho, Anitra Fielding, Jonathan A. Ledermann, J. Carl Barrett

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

    Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZO... حسب Paulo M. Hoff, Andreas Hochhaus, Bernhard C. Pestalozzi, Niall C. Tebbutt, Jin Li, Tae Won Kim, Krassimir Koynov, G. Kurteva, Tamás Pintér, Ying Cheng, Brigitte Van Eyll, Laura A. Pike, Anitra Fielding, Jane Robertson, Mark Saunders

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a <scp><i>BRCA</i></scp> mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

    Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a <scp><i>BRCA</i></scp> mutation: Overall survival adjusted for postprogressio... حسب Ursula A. Matulonis, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Stuart Spencer, David Parry, Lynda Grinsted, Jonathan A. Ledermann

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation

    Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation حسب Bella Kaufman, Ronnie Shapira‐Frommer, Rita K. Schmutzler, M. William Audeh, Michael Friedlander, Judith Balmañà, Gillian Mitchell, Georgeta Fried, Salomon M. Stemmer, Ayala Hubert, Ora Rosengarten, Mariana Steiner, Niklas Loman, Karin Bowen, Anitra Fielding, Susan M. Domchek

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

    Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer حسب Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Bryan Bennett, David Parry, Stuart Spencer, Helen Mann, Ursula A. Matulonis

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

    An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib حسب Joaquı́n Mateo, Víctor Moreno, Avinash Gupta, S.B. Kaye, Emma Dean, Mark R. Middleton, Michael Friedlander, Charlie Gourley, Ruth Plummer, Gordon Rustin, C. Sessa, Karin Leunen, Jonathan A. Ledermann, Helen Swaisland, Anitra Fielding, Wendy Bannister, Shibani Nicum, L Rhoda Molife

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

    Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-cont... حسب Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Stuart Spencer, Philip Rowe, Elizabeth Lowe, Darren Hodgson, Mika A. Sovak, Ursula A. Matulonis

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

    Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02 حسب Ana Oaknin, Jung‐Yun Lee, Vicky Makker, Do‐Youn Oh, Susana Banerjee, Antonio González-Martı́n, Kyung Hae Jung, Iwona Ługowska, Luís Manso, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Soham D. Puvvada, Ann Smith, Funda Meric‐Bernstam

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics

    A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging... حسب Claire L. Mitchell, James P.B. O’Connor, Caleb Roberts, Y. Watson, Alan Jackson, Susan Cheung, Jeffrey Evans, James Spicer, Adrian L. Harris, Claudia S. Kelly, S. M. Rudman, Mark R. Middleton, Anitra Fielding, Jean Tessier, Helen Young, Geoff J.M. Parker, Gordon C. Jayson

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

    Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial حسب Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, Do‐Youn Oh, Susana Banerjee, Antonio González-Martı́n, Kyung Hae Jung, Iwona Ługowska, Luís Manso, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Yan Ma, Soham D. Puvvada, Norah J. Shire, Jung‐Yun Lee

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer

    Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer حسب Lawrence Leichman, Susan Groshen, Bert H. O’Neil, Wells A. Messersmith, Jordan Berlin, Emily Chan, Cynthia G. Leichman, Steven J. Cohen, Deirdre Jill Cohen, Heinz‐Josef Lenz, Philip J. Gold, Bruce M. Boman, Anitra Fielding, Gershon Y. Locker, Ronald C. Cason, S. R. Hamilton, Howard S. Höchster

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

    Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes حسب Darren Hodgson, Brian Dougherty, Zhongwu Lai, Anitra Fielding, Lynda Grinsted, Stuart Spencer, Mark J. O’Connor, Tony W. Ho, Jane Robertson, Jerry S. Lanchbury, Kirsten M. Timms, Alexander Gutin, Maria Orr, Helen Jones, C. Blake Gilks, Chris Womack, Charlie Gourley, Jonathan A. Ledermann, J. Carl Barrett

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

    Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies حسب Luc Dirix, Helen Swaisland, Henk M.W. Verheul, Sylvie Rottey, Karin Leunen, Guy Jérusalem, Christian Rolfo, Dorte Nielsen, L. Rhoda Molife, Rebecca Kristeleit, Judith de Vos‐Geelen, Morten Mau‐Sørensen, Patricia M.M.B. Soetekouw, Carla van Herpen, Anitra Fielding, Karen So, Wendy Bannister, Ruth Plummer

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

    Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules fol... حسب Michael Friedlander, Ursula A. Matulonis, Charlie Gourley, Andreas du Bois, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Vadim Shirinkin, Frédèric Selle, Anitra Fielding, Elizabeth Lowe, Emma McMurtry, Stuart Spencer, Philip Rowe, Helen Mann, David Parry, Jonathan A. Ledermann

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer

    Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer حسب Andrew Tutt, Judy E. Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña, Susan M. Domchek, Karen A. Gelmon, Simon J. Hollingsworth, Larissa A. Korde, Barbro Linderholm, Hanna Bandos, Elżbieta Senkus, Jennifer M. Suga, Zhimin Shao, Andrew W. Pippas, Zbigniew Nowecki, Tomasz Huzarski, Patricia A. Ganz, Peter C. Lucas, Nigel Baker, Sibylle Loibl, Robin McConnell, Martine Piccart, Rita K. Schmutzler, Guenther G. Steger, Joseph P. Costantino, Amal Arahmani, Norman Wolmark, Eleanor McFadden, Vassiliki Karantza, Sunil R. Lakhani, Greg Yothers, Christine Campbell, Charles E. Geyer

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer حسب Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross, Priya Rastogi, Karen Cui, Amal Arahmani, Gursel Aktan, Anne Armstrong, Mónica Arnedos, Judith Balmaña, Jonas Bergh, Judith M. Bliss, Suzette Delaloge, Susan M. Domchek, Andrea Eisen, F. Elsafy, L.E. Fein, Anitra Fielding, James M. Ford, Sue Friedman, Karen A. Gelmon, Luca Gianni, Michael Gnant, Simon J. Hollingsworth, Seock‐Ah Im, Agnes Jager, Oskar T. Johannsson, Sunil R. Lakhani, W Janni, Barbro Linderholm, T.-W. Liu, Niklas Loman, Larissa A. Korde, Sibylle Loibl, Peter C. Lucas, Frederik Marmé, E. Martinez de Dueñas, Robin McConnell, Kelly‐Anne Phillips, Martine Piccart, Giovanna Rossi, Rita K. Schmutzler, Elżbieta Senkus, Zhi-Ming Shao, Priyanka Sharma, Christian F. Singer, Tanja Španić, Elmar Stickeler, Masakazu Toi, Tiffany A. Traina, Giuseppe Viale, Gabriele Zoppoli, Y.H. Park, Rinat Yerushalmi, Huan Yang, D. Pang, Kyung Hae Jung, Audrey Mailliez, Zhaoqing Fan, Isabelle Tennevet, J. Zhang, T. Nagy, Gabe S. Sonke, Qiuhong Sun, Marina Parton, Marco Colleoni, Marcus Schmidt, Adam Brufsky, W. Razaq, Bella Kaufman, David Cameron, Christine Campbell, Andrew Tutt, P. Sevelda, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F. Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, A. Weltermann, Daniel Egle, I. Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser‐Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: